NO20023953D0 - Pyridinylimidazoler - Google Patents
PyridinylimidazolerInfo
- Publication number
- NO20023953D0 NO20023953D0 NO20023953A NO20023953A NO20023953D0 NO 20023953 D0 NO20023953 D0 NO 20023953D0 NO 20023953 A NO20023953 A NO 20023953A NO 20023953 A NO20023953 A NO 20023953A NO 20023953 D0 NO20023953 D0 NO 20023953D0
- Authority
- NO
- Norway
- Prior art keywords
- pyridinylimidazoler
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0004053A GB0004053D0 (en) | 2000-02-21 | 2000-02-21 | Compounds |
| GB0015902A GB0015902D0 (en) | 2000-06-28 | 2000-06-28 | Compounds |
| PCT/GB2001/000736 WO2001062756A1 (en) | 2000-02-21 | 2001-02-21 | Pyridinylimidazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20023953D0 true NO20023953D0 (no) | 2002-08-20 |
| NO20023953L NO20023953L (no) | 2002-10-21 |
Family
ID=26243690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20023953A NO20023953L (no) | 2000-02-21 | 2002-08-20 | Pyridinylimidazoler |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030166633A1 (no) |
| EP (1) | EP1257543A1 (no) |
| JP (1) | JP2003524010A (no) |
| KR (1) | KR20020073597A (no) |
| CN (1) | CN1404478A (no) |
| AR (1) | AR029803A1 (no) |
| AU (2) | AU2001233918B2 (no) |
| BR (1) | BR0108437A (no) |
| CA (1) | CA2401036A1 (no) |
| CO (1) | CO5271680A1 (no) |
| CZ (1) | CZ20022852A3 (no) |
| HU (1) | HUP0204514A3 (no) |
| IL (1) | IL151319A0 (no) |
| MX (1) | MXPA02008082A (no) |
| NO (1) | NO20023953L (no) |
| NZ (1) | NZ520753A (no) |
| PL (1) | PL357420A1 (no) |
| WO (1) | WO2001062756A1 (no) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002040468A1 (en) * | 2000-11-16 | 2002-05-23 | Smithkline Beecham Corporation | Compounds |
| GB0127433D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| GB0127430D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| WO2003097639A1 (en) * | 2002-05-15 | 2003-11-27 | Smithkline Beecham Corporation | Benzoxazine and benzoxazinone substituted triazoles |
| EP1575506A4 (en) * | 2002-07-25 | 2008-04-23 | Scios Inc | METHOD FOR IMPROVING LUNG FUNCTION WITH TGF-BETA INHIBITORS |
| US20040146509A1 (en) * | 2002-07-25 | 2004-07-29 | Zhihe Li | Methods for improvement of lung function using TGF-beta inhibitors |
| UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| DE60327443D1 (de) | 2002-09-18 | 2009-06-10 | Pfizer Prod Inc | Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf) |
| EA200500286A1 (ru) | 2002-09-18 | 2005-08-25 | Пфайзер Продактс Инк. | Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр) |
| CN1681805A (zh) | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物 |
| JP4519657B2 (ja) | 2002-09-18 | 2010-08-04 | ファイザー・プロダクツ・インク | 形質転換成長因子（ｔｇｆ）阻害剤としての新規なピラゾ−ル化合物 |
| AP2005003260A0 (en) | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Novel triazole compounds as transforming growth factor (TGF) inhibitors. |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| US7368445B2 (en) | 2004-03-01 | 2008-05-06 | Eli Lilly And Company | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms |
| CN100584842C (zh) | 2004-03-05 | 2010-01-27 | 大正制药株式会社 | 噻唑衍生物 |
| CA2556944C (en) | 2004-03-05 | 2012-10-09 | Taisho Pharmaceutical Co., Ltd. | Thiazole derivative |
| US20080319012A1 (en) * | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| KR100749566B1 (ko) * | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| EP1798229A4 (en) * | 2004-09-07 | 2009-07-29 | Sankyo Co | SUBSTITUTED BIPHENYL DERIVATIVE |
| BRPI0612124A2 (pt) * | 2005-06-24 | 2010-10-19 | Genelabs Tech Inc | derivados de heteroarila para o tratamento de viroses |
| KR100694181B1 (ko) * | 2005-11-25 | 2007-03-12 | 연세대학교 산학협력단 | 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법 |
| WO2008071605A2 (en) * | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| HUE033195T2 (en) | 2007-08-03 | 2017-11-28 | Summit (Oxford) Ltd | Combinations of drugs for the treatment of Duchenne muscular dystrophy |
| WO2009047163A1 (en) * | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| EA201001456A1 (ru) * | 2008-03-21 | 2011-06-30 | Новартис Аг | Новые гетероциклические соединения и их применение |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| US8586581B2 (en) | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8513222B2 (en) | 2010-06-29 | 2013-08-20 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| USRE47141E1 (en) | 2010-06-29 | 2018-11-27 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| TWI410425B (zh) * | 2010-12-03 | 2013-10-01 | Lilly Co Eli | 唑并［５，４－ｂ］吡啶－５－基化合物 |
| PL2731949T3 (pl) | 2011-07-13 | 2018-10-31 | Tiumbio Co., Ltd. | 2-pirydylo podstawione imidazole jako inhibitory alk5 i/lub alk4 |
| WO2013019561A1 (en) * | 2011-07-29 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| PT2736887T (pt) | 2011-07-29 | 2018-01-15 | Karyopharm Therapeutics Inc | Modeladores de transporte nuclear contendo hidrazida e utilizações dos mesmos |
| KR20200115688A (ko) | 2012-05-09 | 2020-10-07 | 바이오젠 엠에이 인코포레이티드 | 핵 수송 조절인자 및 이의 용도 |
| CN104520422B (zh) | 2012-05-30 | 2019-08-23 | 康奈尔大学 | 由人羊水来源的细胞生成功能性的和持久的内皮细胞 |
| RS60318B1 (sr) | 2012-08-01 | 2020-07-31 | Ikaika Therapeutics Llc | Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitela |
| WO2014130770A1 (en) | 2013-02-22 | 2014-08-28 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| EP2968278B8 (en) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| AU2014275130B2 (en) | 2013-06-05 | 2019-09-12 | Reverse Bioengineering, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
| ME03421B (me) | 2013-06-21 | 2020-01-20 | Karyopharm Therapeutics Inc | 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| WO2015164228A1 (en) | 2014-04-21 | 2015-10-29 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
| US10100031B2 (en) | 2014-04-22 | 2018-10-16 | Universitaet Basel | Manufacturing process for triazine, pyrimidine and pyridine derivatives |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| EA201790384A1 (ru) | 2014-08-15 | 2017-08-31 | Кариофарм Терапевтикс, Инк. | Полиморфы селинексора |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| WO2017117529A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US10709706B2 (en) | 2015-12-31 | 2020-07-14 | Karopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| KR102434226B1 (ko) * | 2016-06-30 | 2022-08-19 | 한미약품 주식회사 | Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도 |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| US10961239B2 (en) | 2017-01-05 | 2021-03-30 | Bristol-Myers Squibb Company | TGF beta receptor antagonists |
| GB201718285D0 (en) * | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
| EP3894401A2 (en) | 2018-12-11 | 2021-10-20 | Theravance Biopharma R&D IP, LLC | Naphthyridine and quinoline derivatives useful as alk5 inhibitors |
| CA3124415A1 (en) | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
| KR20210111313A (ko) * | 2019-01-22 | 2021-09-10 | 주식회사 비씨켐 | 에이엘케이4/5 억제제인 융합된 고리 헤테로아릴 화합물 |
| WO2021011834A1 (en) * | 2019-07-16 | 2021-01-21 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
| IL293084A (en) * | 2019-11-22 | 2022-07-01 | Theravance Biopharma R& D Ip Llc | 5,1-Converted naphthyridines or quinolines as alk5 inhibitors |
| CN115052663A (zh) | 2020-01-08 | 2022-09-13 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
| AR122711A1 (es) * | 2020-06-25 | 2022-09-28 | Alchemedicine Inc | COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA |
| TW202216682A (zh) * | 2020-07-01 | 2022-05-01 | 美商希沃爾拜克治療公司 | Alk5 抑製劑、共軛物及其用途 |
| US20240116947A1 (en) | 2020-07-15 | 2024-04-11 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| AU2021307560A1 (en) | 2020-07-15 | 2023-02-23 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine amino derivatives as ALK5 inhibitors |
| KR20230051500A (ko) | 2020-07-15 | 2023-04-18 | 키에시 파르마슈티시 엣스. 피. 에이. | Alk5 억제제로서 피리다진일 아미노 유도체 |
| US20240116948A1 (en) | 2020-12-23 | 2024-04-11 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| WO2023046698A1 (en) | 2021-09-21 | 2023-03-30 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
| CN114380823B (zh) * | 2022-01-26 | 2023-06-23 | 中国药科大学 | 咪唑-2-甲胺类衍生物及其医药用途 |
| WO2023208986A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
| CN115466260B (zh) * | 2022-09-06 | 2023-10-13 | 延边大学 | 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH561716A5 (no) * | 1971-05-10 | 1975-05-15 | Ciba Geigy Ag | |
| IL104369A0 (en) * | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
| US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
| ZA945363B (en) * | 1993-07-21 | 1995-03-14 | Smithkline Beecham Corp | Novel compounds |
| JPH09124640A (ja) * | 1995-08-25 | 1997-05-13 | Nippon Soda Co Ltd | ピリジルイミダゾール化合物、製法および農園芸用殺菌剤 |
| AU8757098A (en) * | 1997-06-30 | 1999-02-10 | Ortho-Mcneil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
| US6207687B1 (en) * | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
-
2001
- 2001-02-20 CO CO01013429A patent/CO5271680A1/es not_active Application Discontinuation
- 2001-02-20 AR ARP010100755A patent/AR029803A1/es not_active Application Discontinuation
- 2001-02-21 EP EP01905954A patent/EP1257543A1/en active Pending
- 2001-02-21 NZ NZ520753A patent/NZ520753A/en unknown
- 2001-02-21 CA CA002401036A patent/CA2401036A1/en not_active Abandoned
- 2001-02-21 BR BR0108437-2A patent/BR0108437A/pt not_active IP Right Cessation
- 2001-02-21 IL IL15131901A patent/IL151319A0/xx unknown
- 2001-02-21 AU AU2001233918A patent/AU2001233918B2/en not_active Ceased
- 2001-02-21 CZ CZ20022852A patent/CZ20022852A3/cs unknown
- 2001-02-21 AU AU3391801A patent/AU3391801A/xx active Pending
- 2001-02-21 KR KR1020027010853A patent/KR20020073597A/ko not_active Application Discontinuation
- 2001-02-21 US US10/204,370 patent/US20030166633A1/en not_active Abandoned
- 2001-02-21 CN CN01805374A patent/CN1404478A/zh active Pending
- 2001-02-21 PL PL01357420A patent/PL357420A1/xx not_active Application Discontinuation
- 2001-02-21 JP JP2001562538A patent/JP2003524010A/ja active Pending
- 2001-02-21 HU HU0204514A patent/HUP0204514A3/hu unknown
- 2001-02-21 MX MXPA02008082A patent/MXPA02008082A/es unknown
- 2001-02-21 WO PCT/GB2001/000736 patent/WO2001062756A1/en not_active Application Discontinuation
-
2002
- 2002-08-20 NO NO20023953A patent/NO20023953L/no not_active Application Discontinuation
-
2004
- 2004-01-29 US US10/767,943 patent/US20040220230A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020073597A (ko) | 2002-09-27 |
| US20030166633A1 (en) | 2003-09-04 |
| CA2401036A1 (en) | 2001-08-30 |
| CO5271680A1 (es) | 2003-04-30 |
| CZ20022852A3 (cs) | 2003-04-16 |
| HUP0204514A3 (en) | 2004-07-28 |
| US20040220230A1 (en) | 2004-11-04 |
| HUP0204514A2 (en) | 2003-05-28 |
| IL151319A0 (en) | 2003-04-10 |
| MXPA02008082A (es) | 2003-02-27 |
| NZ520753A (en) | 2004-08-27 |
| PL357420A1 (en) | 2004-07-26 |
| AU3391801A (en) | 2001-09-03 |
| CN1404478A (zh) | 2003-03-19 |
| JP2003524010A (ja) | 2003-08-12 |
| AR029803A1 (es) | 2003-07-16 |
| EP1257543A1 (en) | 2002-11-20 |
| WO2001062756A1 (en) | 2001-08-30 |
| AU2001233918B2 (en) | 2004-06-24 |
| NO20023953L (no) | 2002-10-21 |
| BR0108437A (pt) | 2005-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE290000T1 (de) | Muscarinagonisten | |
| ATE252099T1 (de) | Biarylcarboxamide | |
| DE10136334B8 (de) | Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser | |
| ATE312098T1 (de) | Thiazinoxazolidinon | |
| ATA2932001A (de) | Schneefräse | |
| DE50102988D1 (de) | Bodenwischer | |
| DE50104056D1 (de) | Gewichtsmanschette | |
| DE50100710D1 (de) | Wischblatt | |
| ATE262530T1 (de) | Indolochinazolinone | |
| ATE298751T1 (de) | 7-oxopyridoryrimidine | |
| DE1274523T1 (de) | Hochdruckumformspülanlage | |
| DE50104651D1 (de) | Fahrzeugfaltverdeck | |
| DE10192638T1 (de) | Bohrstangenladevorrichtung | |
| AR028336A1 (es) | 4-hidroxi-tetrahidropiridonas fenilsubstituidas | |
| ATE509008T1 (de) | Sulfonylguanidine | |
| DE10196064T1 (de) | Halbleiterfotodektionsgerät | |
| DE50100817D1 (de) | Kugelgelenk | |
| AR028061A1 (es) | 2-enamino-cetonitrilos fenil-substituidos | |
| AR027931A1 (es) | Antitranspirantes | |
| DE50007634D1 (de) | Kardioplegieballonkatheter | |
| ATE476423T1 (de) | Benzoylpyridazine | |
| DE10052925B4 (de) | Schaukelbett | |
| DE10085445T1 (de) | Drahterodierbearbeitungseinrichtung | |
| AR027982A1 (es) | Aril- y heteroarilsulfonatos | |
| DE10195909T1 (de) | Viehfüttervorrichtung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |